In the rat kidney, the AT1 receptor is the predominant Angiotensin II receptor subtype, accounting for 95% of total receptors.
AT1 predominance in rat kidney supports targeted RAAS modeling; leaves open human translation and clinical relevance.
Angiotensin II (Ang II) receptor subtypes in the rat kidney were investigated by using type 1 (AT₁) and type 2 (AT₂) Ang II receptor antagonists to discriminate specific ¹²⁵I-[Sar¹, Ile⁸] Ang II binding sites with in vitro autoradiography. DuP 753, a nonpeptide Ang II antagonist specific for the AT₁ sites, potently displaced binding in glomeruli (Ki = 23.9 ± 3.3 nM) and proximal tubules (Ki = 43.4 ± 17 nM). By contrast, the AT₂antagonists, PD 123177 and CGP 42112A, were very weak in competing for specific ¹²⁵I-[Sar¹, Ile⁸] Ang II binding sites. AT₁ receptors, as determined in the presence of an excess concentration (10 µM) of the AT₂ antagonist, PD 123177, account for 95% of total renal Ang II receptors, whereas AT₂ receptors, as determined in the presence of an excess concentration (10 µM) of the AT₁ antagonist, DuP 753, represent approximately 5% of total 0renal Ang II receptors. In addition, the reducing agent, dithiothreitol, produces a dose-dependent inhibition of Ang II receptor binding with an IC₅₀ of 2 mM, a characteristic of the AT₁ receptors. These findings indicate that the AT₁ receptor is the predominant subtype at multiple anatomical sites in the rat kidney.
No takes yet. Share an insight, caveat, or question.
Zhuo et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: